AOR-FTO
Freedom To Operate – Patent Portfolio Aorticlab
Scheda del progetto
Aorticlab, needs to consolidate its patent portfolio for its developing products (FLOWer and Gemini). To this end, it plans to initiate a Freedom-To-Operate (FTO) analysis to ensure that the devices can be introduced into specific target markets without infringing on third-party patent rights and to identify any potential risks. This service will be conducted using digital technologies, such as patent analysis databases and FTO analysis software, which utilize artificial intelligence algorithms and enable Big Data analysis.
Contact:
Franco Osta
Aorticlab is developing two innovative medical devices for the treatment of aortic stenosis: FLOWer and Gemini. To ensure market success, the company needs to consolidate its patent portfolio and verify the Freedom-To-Operate (FTO) for its products. This analysis is crucial to avoid intellectual property infringements and to strengthen the market entry strategy, improving patient quality of life and contributing to the goals of preventive medicine.
Aorticlab is developing the medical devices FLOWer and Gemini to address issues in aortic stenosis. For market entry, it is crucial to pass pre-clinical and clinical tests and to strengthen intellectual property through a Freedom-To-Operate (FTO) analysis. This service, based on digital technologies and artificial intelligence algorithms, faces no technical obstacles and will be managed through online meetings to optimize time and costs.
Aorticlab is obtaining authorization for the launch of two products: FLOWer in Europe and Gemini in the United States. The FTO analysis will verify the freedom to operate in the target countries, consolidating Marketing&Sales strategies. These results will strengthen the company's competitive advantage and demonstrate the value of the products to investors. FTO analyses are crucial for the commercialization of medical devices and will also benefit end users by providing new solutions for patients.